215 related articles for article (PubMed ID: 32671898)
1. Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma.
Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
Head Neck; 2020 Nov; 42(11):3275-3281. PubMed ID: 32671898
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
5. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
7. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
[TBL] [Abstract][Full Text] [Related]
8. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
10. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.
Leddon JL; Gulati S; Haque S; Allen C; Palackdharry S; Mathews M; Kurtzweil N; Riaz MK; Takiar V; Nagasaka M; Patil Y; Zender C; Tang A; Cervenka B; McGrath J; Korn WM; Hinrichs BH; Jandarov R; Harun N; Sukari A; Wise-Draper TM
Clin Cancer Res; 2022 Aug; 28(16):3464-3472. PubMed ID: 35653116
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K
Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
14. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH; Li J; Steuer CE; Bhateja P; Johnson M; Masannat J; Poole MI; Song F; Hernandez-Prera JC; Molina H; Wenig BM; Kumar S; Kuperwasser C; Stephens PJ; Farinhas JM; Shin DM; Kish JA; Muzaffar J; Kirtane K; Rocco JW; Schell MJ; Saba NF; Bonomi M
Clin Cancer Res; 2022 Jun; 28(11):2329-2338. PubMed ID: 35344035
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
[TBL] [Abstract][Full Text] [Related]
16. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
18. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
Okamoto I; Tsukahara K; Sato H
Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]